Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib Extension Study for CLL
NCT01539291Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2012
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Oct 2012; status: terminated.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01539291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01539291.